POS1395 NEUROFILAMENT LIGHT CHAIN, AN EARLY BIOMARKER FOR POLYNEUROPATHY IN HEREDITARY ATTR AMYLOIDOSIS

Background

Serum neurofilament light chain (sNfL) is a sensitive marker for polyneuropathy (PNP) in hereditary transthyretin-related (ATTRv) amyloidosis patients and correlates with the severity of polyneuropathy [1-4]. We hypothesized that sNfL may diagnose neuronal damage in patients with hATTR amyloidosis before the onset of symptoms and before PNP can be detected by electromyography (EMG) examination.

Objectives

To establish the course of sNfL in three different groups: 1. persistently asymptomatic variant carriers (with and without detected amyloid), 2. ATTRv amyloidosis patients with PNP on treatment, 3. variant carriers who develop PNP.

Methods

sNfL levels were assessed longitudinally in asymptomatic variant carriers (with and without detectable amyloid), ATTRv amyloidosis patients with PNP on treatment (either a transthyretin (TTR) stabilizer or patisiran, an RNA interference therapeutic), and variant carriers who developed PNP. PNP was established by EMG examination. The single-molecule array (Simoa) assay was used to assess sNfL levels.

Results

sNfL levels significantly increased over 1 year in 20 persistently asymptomatic carriers (p<0.001), with the strongest increase in variant carriers (n=8) with detectable amyloid in the subcutaneous abdominal fat tissue. In 21 symptomatic ATTRv amyloidosis patient with PNP on treatment with a TTR stabilizer, sNfL levels remained stable over 1 year. In 24 patients treated with patisiran, sNfL levels significantly decreased after 1 year of treatment (p=0.01). In 8 out of 9 variant carriers who developed PNP a rise in the sNfL level could be observed before the onset of symptoms and establishment of PNP by EMG examination (Figure 1).

Figure 1.

Conclusion

sNfL is a marker for early neuronal damage since a rise in sNfL level occurs before abnormalities can be detected by EMG examination. Our data support the use of sNfL in monitoring disease progression, screening asymptomatic variant carriers and monitoring of treatment effect.

References

[1]Louwsma et al. Amyloid 2021;28(1):50-55

[2]Maia et al. Amyloid 2020;27(2):97-102

[3]Kapoor et al. J Perpher nerv syst 2019;24:314-319

[4]Ticau et al. Neurology 2021;96:e412-e422

Disclosure of Interests

Anne Floor Brunger: None declared, Milou Berends: None declared, Johan Bijzet: None declared, Paul van der Zwaag: None declared, Bart-Jan Kroesen: None declared, Charlotte Teunissen: None declared, Sjors in ‘t Veld: None declared, Gea Drost: None declared, Fiete Lange: None declared, Reinold Gans: None declared, Bouke Hazenberg Consultant of: Alnylam and Pfizer, Hans L.A. Nienhuis Consultant of: Alnylam and Pfizer

Streptozotocin-induced diabetic ketoacidosis in a patient with metastatic islet-cell carcinoma

Here we report a severe life-threatening complication of treatment with streptozotocin in a patient with pancreatic island-cell carcinoma. The patient was admitted to the intensive care unit with severe diabetic ketoacidosis which needed aggressive fluid resuscitation and insulin therapy. We believe it is critical to be aware of the symptoms of diabetic ketoacidosis and monitor glucose levels during streptozotocin treatment.

[Ventricular assist device implantation as a bridge to cardiac transplantation in two adolescents with end-stage cardiomyopathy and heart failure as a result of anthracycline use]

In a adolescent women aged 15 and 17 years respectively, severe heart failure developed within a few months of anthracycline chemotherapy given for osteosarcoma. In the guidelines of the European Society of Cardiology, malignancy with a remission duration of less than 5 years is an absolute contraindication to cardiac transplantation. Neither patient was eligible to receive a ventricular assist device (VAD) as a bridge to cardiac transplantation in the Netherlands, but they were accepted in Germany. One patient received a cardiac transplant 13 months later and at the last follow-up check she was in good health with a remission of 3 years. The other patient developed bone metastases 6 months after the VAD implantation. Cardiac transplantation was not a treatment option for her. Dose-dependent cardiotoxicity is a serious complication of the use of anthracyclines. In severe heart failure the prognosis is often worse than in adjuvantly treated malignancies like osteosarcoma. VAD may therefore be a valid option for patients with severe heart failure after anthracycline use for a malignancy. In cases of sustained remission VAD may be the bridge to transplantation.

The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis

Several reports have indicated that the combination of calcipotriol ointment and potent or ultrapotent corticosteroids are more effective and better tolerated, as compared to the monotherapies. The aim of the present study was to find out the effect of combination of calcipotriol ointment once daily and betamethasone dipropionate ointment once daily vs. the effect of twice-daily applications of each of the two treatments as monotherapy during a four-week treatment period. Seven patients with chronic plaque psoriasis were included for treatment with the three treatment schedules. Biopsies were taken before treatment and after four weeks of treatment, and markers for epidermal proliferation (Ki-67) and epidermal differentiation (keratin-10) were studied using a quantitative image analysis, and T-cell subsets in epidermis and dermis (CD4, CD8, CD25, CD45RO, CD45RA, CD94, CD161, and CD2) were studied using immunohistochemical scoring. The most impressive clinical result was reached with the combination. Calcipotriol proved to have a major effect on the proliferation marker Ki-67 and differentiation marker keratin-10, whereas the effect on T-cell subsets was more selective with major reductions of CD45RO(+) and CD8(+) T cells. In contrast, the effect of betamethasone dipropionate on the epidermis was restricted to a normalization of differentiation with a highly significant increase of keratin-10 positive epidermal surface without a significant effect on Ki-67 positive nuclei, and the effect on T-cell subsets was restricted to a reduction of natural killer T-cell receptors designated by CD94 and CD161 in the epidermis. The combination of the two treatments did not affect the proliferation marker Ki-67 and keratinization marker keratin-10, beyond the effect of calcipotriol monotherapy. However, the combination had a profound effect on, virtually, all T-cell subsets, beyond the effect of the monotherapies. It is concluded that the action spectra of calcipotriol and betamethasone on the psoriatic plaque are different and that the combination has effects on T-cell subsets, beyond the addition of the effects of monotherapies.